Nasdaq:IMCR
Immunocore Holdings plc
A clinical-stage immuno-oncology developer utilizing a proprietary synthetic biology platform to create targeted T-cell engagers for solid tumors.
Key Metrics
Investment Thesis
Bull Case
Immunocore offers a compelling opportunity for investors seeking exposure to breakthrough solid tumor therapies, backed by a robust cash hoard of nearly half a billion dollars that insulates it from short-term market volatility. The company's proprietary synthetic biology platform represents a significant technological moat that could yield first-in-class assets with superior safety profiles compared to traditional immunotherapies. If any of its clinical candidates achieve regulatory approval, the potential upside from licensing deals and royalties could result in substantial shareholder value creation.
Bear Case
The stock carries high risk due to a deep retained earnings deficit of over $831 million and a consistent trend of widening net losses across the last three years. Investors should be wary that the current revenue model relies heavily on one-time milestones rather than sustainable product sales, making valuation difficult without clear clinical success data. The company's heavy burn rate in research and development, combined with limited operating profitability, suggests it may require additional equity financing or asset sales to survive.
About Immunocore Holdings plc
Immunocore Holdings plc is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies to treat solid tumors. The company leverages its proprietary synthetic biology platform to create highly specific T-cell engagers that bypass the need for patient-specific cell manufacturing. Operating primarily in the United States and Europe, Immunocore aims to accelerate cancer treatment options through its innovative pipeline of next-generation immunotherapies.
Analysis
Management Discussion
While revenue grew significantly to $400 million in 2025 driven by licensing milestones, the company continues to report substantial net losses of $35.5 million as R&D expenditures reached $274.9 million. The strong cash position and positive free cash flow adjustments from financing activities provide liquidity, yet the negative operating profit indicates that commercialization efforts have not yet offset the high costs of clinical development. Management's ability to maintain this financial runway while advancing its pipeline into later-stage trials will be critical for future valuation.
Industry Overview
The immuno-oncology sector is highly competitive with a crowded landscape of checkpoint inhibitors and cell therapies, yet solid tumors remain a major unmet medical need where current treatments often fail. Regulatory pathways for novel cellular products are evolving rapidly, creating opportunities for innovative platforms but also increasing the bar for clinical validation. Success in this industry requires significant capital investment over long periods to navigate clinical trials before achieving commercial milestones.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $249.4M | $310.2M | $400.0M |
| Cost of Revenue | $1.0M | $2.7M | $5.1M |
| Gross Profit | $248.4M | $307.5M | $394.9M |
| Operating Expenses | $308.0M | $377.9M | $440.3M |
| Operating Income | $-59.6M | $-70.5M | $-45.4M |
| R&D | $163.5M | $222.2M | $274.9M |
| G&A | $144.5M | $155.8M | $165.4M |
| Stock-Based Comp | $32.5M | $34.2M | $37.7M |
| D&A | $4.1M | $4.2M | $3.1M |
| Depreciation | $4.1M | $4.2M | $3.3M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-1.2M | $17.5M | $26.3M |
| Interest Expense | $5.2M | — | — |
| Interest Income | $18.0M | $25.6M | $16.5M |
| Pre-Tax Income | $-60.9M | $-52.9M | $-19.1M |
| Income Tax | $-5.6M | $-1.9M | $16.4M |
| Continuing Ops | $-55.3M | $-51.1M | $-35.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-55.3M | $-51.1M | $-35.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-55.3M | $-51.1M | $-35.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $528.8M | $929.9M | $996.7M |
| Cash & Equivalents | $442.6M | $455.7M | $467.7M |
| Marketable Securities | — | $364.6M | $396.4M |
| Accounts Receivable | $52.1M | $63.0M | — |
| Inventory | $4.5M | $5.4M | $6.7M |
| Prepaid Expenses | $29.6M | $41.0M | $50.1M |
| Other Current Assets | $0 | $0 | $75.8M |
| Long-Term Assets | $68.2M | $79.6M | $70.5M |
| PP&E (Net) | $9.2M | $10.1M | $11.5M |
| Operating Leases | $33.5M | $37.6M | $38.8M |
| Other LT Assets | $25.4M | $31.9M | $20.3M |
| Total Assets | $597.0M | $1.01B | $1.07B |
| Current Liabilities | $139.0M | $212.2M | $246.7M |
| Accounts Payable | $17.8M | $25.1M | $24.4M |
| Current Leases | $1.4M | $1.5M | $2.0M |
| Deferred Revenue | — | — | $583.0K |
| Other Current Liab | $119.8M | $185.5M | $219.7M |
| Long-Term Liabilities | $89.1M | $436.6M | $439.5M |
| LT Operating Leases | $34.6M | $40.2M | $41.6M |
| Other LT Liab | $54.5M | $396.4M | $393.1M |
| Total Liabilities | $228.2M | $648.8M | $686.2M |
| Shareholders' Equity | $368.8M | $360.7M | $381.0M |
| Paid-In Capital | $1.15B | $1.19B | $1.24B |
| Retained Earnings | $-744.7M | $-795.8M | $-831.3M |
| AOCI | $-36.3M | $-33.8M | $-28.1M |
| Total L&E | $597.0M | $1.01B | $1.07B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-55.3M | $-51.1M | $-35.5M |
| Non-Cash Adjustments | $3.8M | $-32.0M | $-6.4M |
| Working Capital Changes | $54.5M | $109.1M | $31.2M |
| Cash from Operations | $2.9M | $26.1M | $-10.7M |
| Capital Expenditures | $5.4M | $5.2M | $4.3M |
| Cash from Investing | $-5.4M | $-355.1M | $-16.3M |
| Cash from Financing | $34.3M | $343.9M | $12.4M |
| FX Effect | $8.3M | $-1.7M | $26.7M |
| Net Change in Cash | $31.9M | $14.8M | $-14.7M |
| Beginning Cash | $402.5M | $442.6M | $455.7M |
| Ending Cash | $442.6M | $455.7M | $467.7M |
Frequently Asked Questions
How does Immunocore Holdings plc make money?
The company's revenue is currently derived primarily from licensing agreements and milestone payments related to its immuno-oncology pipeline, with a significant portion of recent activity tied to collaborations involving its proprietary IBI series of T-cell engagers. Additionally, the firm generates non-operating income through interest earnings on its substantial cash and marketable securities portfolio, which supports its capital-intensive R&D strategy.
What are the main risks for IMCR?
The company faces significant risk due to persistent net losses and a widening operating deficit, as current operations consumed approximately $45 million in operating profit last year. Progress of its clinical programs remains unproven, with potential failure at any stage leading to total loss of invested R&D capital including the $275 million spent on research recently. Regulatory hurdles for novel cell-based therapies are substantial and could delay market entry or require costly additional trials. The heavy reliance on non-operating income and cash reserves suggests that without successful product launches, the company will continue to deplete its liquid assets.
What is IMCR's competitive advantage?
Immunocore possesses a unique proprietary synthetic biology platform capable of engineering highly specific T-cell engagers that effectively target solid tumors while minimizing off-target toxicity. The company benefits from a strong balance sheet with over $467 million in cash and equivalents, providing sufficient runway to advance multiple clinical candidates without immediate dilution pressure. Its differentiated approach to overcoming the limitations of traditional checkpoint inhibitors positions it well against established competitors in the crowded oncology space.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.